GlassScriptPhysician profile
Walter K Sosey
NPI 1942276555
$3,125.48
in general payments reported to CMS, 2019-2025
27 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $910 · 2020: $464 · 2021: $652 · 2022: $249 · 2023: $267 · 2024: $340 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $528.35 | 2019-2020 | |
| Lilly USA, LLC | $295.90 | 2019-2023 | Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $264.23 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $241.92 | 2019-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $215.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $196.11 | 2020-2025 | Tezspire, Farxiga |
| Lifenet Health | $157.39 | 2025 | Theragenesis Wound Matrix |
| Si-Bone, INC. | $125.21 | 2021 | |
| Inspire Medical Systems, INC. | $121.09 | 2023 | Inspire |
| Abbvie INC. | $108.76 | 2019 | |
| Medtronic, INC. | $102.93 | 2024 | Venaseal |
| Novo Nordisk INC | $102.11 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.03 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.01 | 2019-2022 | |
| Amgen INC. | $81.82 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $70.01 | 2020-2021 | |
| Mylan Specialty L.P. | $61.79 | 2024 | Yupelri |
| Pfizer INC. | $58.09 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $44.77 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.68 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.02 | 2019 | |
| Boston Scientific Corporation | $23.55 | 2021 | |
| Edwards Lifesciences Corporation | $23.39 | 2025 | |
| Nevro Corp. | $21.32 | 2022 | |
| Dexcom, INC. | $16.08 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.53 | 2019 | |
| Itamar Medical INC | $11.85 | 2024 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Sosey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.